SCHEMBL22290891

SCHEMBL22290891

Cn1c(=O)ccc2ccc(B3OC(C)(C)C(C)(C)O3)cc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 3/20 0.45
CA9 Q16790 3/20 0.45
CA12 O43570 2/20 0.45
BRD4 O60885 1/20 0.45
KAT2B Q92831 1/20 0.45
BRD9 Q9H8M2 1/20 0.45
IRAK4 Q9NWZ3 1/20 0.44
LPL P06858 9/20 0.43
LIPG Q9Y5X9 9/20 0.43
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA3 P07451 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
CA5A P35218 1/20 0.37
CA7 P43166 1/20 0.37
CA14 Q9ULX7 1/20 0.37
CA5B Q9Y2D0 1/20 0.37
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31149544 0.90 BRPF1 (0.50) BRPF1CA9CA12BRD4KAT2B
SCHEMBL4562321 0.90 BRPF1 (0.50) BRPF1CA9CA12BRD4KAT2B
SCHEMBL29038875 0.82 BRPF1 (0.40) BRPF1CA9CA12BRD4KAT2B
SCHEMBL30538023 0.82 BRPF1 (0.40) BRPF1CA9CA12BRD4KAT2B
SCHEMBL16932312 0.81 BRPF1 (0.41) BRPF1CA9CA12BRD4KAT2B
SCHEMBL24145488 0.80 BRPF1 (0.40) BRPF1CA9CA12BRD4KAT2B
SCHEMBL28986406 0.78 IRAK4 (0.42) CA9CA12IRAK4LPLLIPG
SCHEMBL29894116 0.78 IRAK4 (0.46) CA9CA12IRAK4LPLLIPG
SCHEMBL15331596 0.78 SMN1; SMN2 (0.43) BRPF1CA9CA12BRD4IRAK4
SCHEMBL29704393 0.78 SMN1; SMN2 (0.43) BRPF1CA9CA12BRD4IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 EP disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 US disclosed
EP-3917527-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 EP disclosed
CN-113645971-A Compound and use thereof 福宏治疗公司 2021-11-12 CN disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB BRPF1 1120/4885CA9 4577/4885CA12 4343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.